Trials / Completed
CompletedNCT00329355
Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)
A Randomized, Double-blind, Single Migraine Attack, Placebo-controlled, Parallel-group Multicenter Study to Evaluate the Efficacy and Tolerability of Trexima (Sumatriptan Succinate.Naproxen Sodium) Tablets vs Placebo When Administered During the Mild Pain Phase of Menstrual Migraine in Women With Dysmenorrhea
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 351 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to determine efficacy of TREXIMET (sumatriptan/naproxen sodium), formerly known as TREXIMA compared to placebo for the treatment of a menstrual migraine.
Detailed description
A randomized, double-blind, single migraine attack, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and tolerability of TREXIMA\* (sumatriptan succinate/naproxen sodium) tablets vs placebo when administered during the mild pain phase of menstrual migraine in women with dysmenorrhea (\*TREXIMET)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sumatriptan succinate/naproxen sodium |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2006-11-01
- Completion
- 2006-11-01
- First posted
- 2006-05-24
- Last updated
- 2017-01-23
Locations
35 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00329355. Inclusion in this directory is not an endorsement.